{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6sq7wKDA","lastupdate":"2020-10-11T00:00:00.000Z","update_date":"2020-10-11T00:00:00.000Z","lastModified":"Apr 24, 2025","active":1,"confidence_score":97,"confidence_score_reason":"markets, external profiles","urlname":"lipomedix","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$l6sd6NdYllN9AJYbWihtQc1L0HIw2YB2MbyYsAcQJAUMa8IIc4O0E7","name":"LipoMedix","oneliner":"Liposome Delivery for Cancer Therapy ","registrar":"514549997","website":"https://www.lipomedix.com","careerspage":"","founded_month":6,"founded_year":2011,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"","instagram":""},"social":[],"flattenedsociallinks":null,"apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"1-10","employees_exact":6,"patent":1,"raised":56000,"stage":"Pre-Funding","public_stage":"Pre-Funding","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["LIPOMEDIX PHARMACEUTICALS","Lipo Medix"],"about":"LipoMedix Pharmaceuticals is a privately held development-stage company focused on an innovative, safe, and effective cancer therapy based on liposome delivery. The companys lead product, Promitil, has demonstrated antitumor effects in tumor models that rival or outperform the effects of many standard forms of chemotherapy, such as cisplatin, irinotecan, gemcitabine, and doxorubicin, with less toxicity.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97225866177","country":null,"address":{"israeli":[{"id":"5e61f80b-7b06-439d-ba0a-bc8a876546a9","city":"Jerusalem","type":null,"address":"Giv'at Ram, Jerusalem, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Jerusalem District","news":[{"id":"d1d316de-1cb7-476a-842b-190a56c9bf3f","date":"Jan 23, 2020","link":"https://www.globenewswire.com/news-release/2020/01/23/1974347/0/en/LipoMedix-Announces-Publication-of-Positive-Phase-1-Data-for-Promitil-PL-MLP-in-Research-Journal-Investigational-New-Drugs.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Cancer Therapy, Clinical Trials","company":"LipoMedix","layoffs":"N/A","summary":"LipoMedix, a clinical-stage, oncology-focused pharmaceutical company, has announced positive Phase 1 data for its drug, Promitil, in patients with metastatic colorectal cancer. The study, published in the research journal Investigational New Drugs, demonstrated positive results on the pharmacokinetics and clinical observations of the drug. Promitil was well-tolerated with a good safety profile and resulted in a substantial rate of disease stabilization. The treatment resulted in a median survival of 14.4 months, significantly longer than of progressive disease patients. The company plans to further develop Promitil as a novel and smart tool to overcome the problems associated with mitomycin-c toxicity.","partners":"Rafael Holdings, Inc.","customers":"N/A","investors":"Rafael Holdings, Inc.","confidence":"9","key_topics":"Promitil, Metastatic Colorectal Cancer, Clinical Study, Drug Development, Oncology","date_of_event":"January 23, 2020","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Investment","acquisition_amount":"N/A","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZYyd0IdlllyYdXqtiWD9DeIjOnjabd52JKzISCvo7CFIwXPm18rdSK","news_summary":"LipoMedix Announces Publication of Positive Phase 1 Data for Promitil® (PL-MLP) in Research Journal Investigational New Drugs","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f83d3a82-fa10-4390-9dd3-55e4b2a5ce11","date":"Aug 5, 2019","link":"https://www.globenewswire.com/news-release/2019/08/05/1896925/0/en/LipoMedix-Appoints-New-Members-to-Board-of-Directors-and-Creates-New-Executive-Committee.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"board appointments","company":"LipoMedix Pharmaceuticals Ltd.","layoffs":null,"summary":"LipoMedix Pharmaceuticals has announced the addition of Miranda J. Toledano and Praveen Tyle, Ph.D., to its board of directors. The company has also formed an executive committee of the board to enhance governance and support its development. Toledano and Tyle will join Sanjeev Luther, chairman of the board, on the executive committee. Toledano has over 20 years of executive experience in the biopharmaceutical sector, while Tyle is currently the executive vice president of research and development at Lexicon Pharmaceuticals. Alberto Gabizon, M.D., Ph.D., co-founder of LipoMedix, will now serve as president of the company. LipoMedix is focused on the development of an innovative cancer therapy based on liposome delivery.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["board appointments","executive committee","Promitil®","liposome delivery","cancer therapy"],"date_of_event":"August 5, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"31I78vnCnaAhQzWlKoWSX0h5CZKVgjBrGkE1vwHeXKW6VqEsfaxxuR","news_summary":"LipoMedix Appoints New Members to Board of Directors and Creates New Executive Committee","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"163007ec-d34e-4799-aec1-6d65a4fdbbf9","date":"Mar 29, 2019","link":"https://www.globenewswire.com/news-release/2019/03/29/1789730/0/en/LipoMedix-to-Present-New-Clinical-Data-on-Promitil-at-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2019.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"clinical data","company":"LipoMedix","layoffs":null,"summary":"LipoMedix, a clinical-stage pharmaceutical company, announced that new clinical data of Promitil® in patients with metastatic colorectal cancer will be presented at the AACR annual meeting. The study shows disease stabilization and extended survival in a significant fraction of patients. Promitil® is a liposomal drug delivery platform that enables efficient and selective tumor delivery of MLP, a chemical entity known as mitomycin-c lipidic prodrug. The presentation will take place on April 1, 2019.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Promitil","metastatic colorectal cancer","clinical data","liposomal drug delivery platform","AACR annual meeting"],"date_of_event":"April 1, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"E7k7Mh9nDRr0nbfDdRVBjG0vfhNu5sQBsqlMH531zoErqb0gFcn0t7","news_summary":"LipoMedix to Present New Clinical Data on Promitil® at American Association for Cancer Research (AACR) Annual Meeting 2019","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"adb5e299-9826-49f1-b6de-dff053710569","date":"Mar 4, 2019","link":"https://www.globenewswire.com/news-release/2019/03/04/1746224/0/en/Lipomedix-Announces-Initiation-of-Phase-1b-Trial-LIPORAD-2018-of-Promitil-in-Combination-with-Radiotherapy-in-Patients-with-Advanced-Cancer.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"clinical trial","company":"LipoMedix","layoffs":null,"summary":"LipoMedix, a clinical-stage pharmaceutical company, has announced the initiation of a Phase 1b multicenter trial to evaluate the safety and efficacy of its lead compound Promitil® in combination with external beam radiotherapy (EBR) for advanced cancer patients. The trial, approved by Israels Ministry of Health, is expected to be completed by Q1 2020. Promitil® is a liposomal prodrug of mitomycin C, which has shown promising clinical activity as a treatment for metastatic colon cancer and has the potential to become a curative tool in chemo-radiotherapy. LipoMedix plans to develop Promitil® for other difficult-to-treat cancers as well. Investors in LipoMedix include Rafael Holdings. The company aims to deliver efficient and selective tumor delivery of Promitil® through its pegylated liposome delivery platform.","partners":null,"customers":null,"investors":"Rafael Holdings","confidence":9,"key_topics":["Phase 1b trial","Promitil®","Radiotherapy","Cancer therapy","Liposomal drug delivery"],"date_of_event":"March 04, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4QGse8CUGVo2vAFloMFc8HXMiTJuvBhYw8DkVYNXfVmKXSdTGKdjjj","news_summary":"Lipomedix Announces Initiation of Phase 1b Trial (LIPORAD-2018) of Promitil® in Combination with Radiotherapy in Patients with Advanced Cancer.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":4,"techcommunityinvolvement":null,"mediagallery":[{"id":"402d51b3-51a9-4e22-ba12-dc3f768bd85b","timestamp":"2016-04-10 07:04:28.000000","resources_type":1,"resources_title":"","resources_file_name":"$8xFmireokaa7tdfhocKNLnu0axv6f4SFhL06Urt8VUIQ9WhbgM2zWZ","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$8xFmireokaa7tdfhocKNLnu0axv6f4SFhL06Urt8VUIQ9WhbgM2zWZ","url":"https://storage.googleapis.com/clean-finder-353810/$8xFmireokaa7tdfhocKNLnu0axv6f4SFhL06Urt8VUIQ9WhbgM2zWZ"}],"tags":["cancer","oncology","biopharmaceutical","drug-delivery","targeted-therapy","chemotherapy","therapeutics","pharmaceuticals","pharma-companies"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA"],"technologysuccessstory":[{"date":"2013-01-01","name":"Pegylated liposome delivery system platform based on the encapsulation of a new chemical entity known as MLP","tags":["targeted-therapy","drug-delivery","biopharmaceutical","oncology","chemotherapy"],"category":"Pharmaceuticals & Diagnostics","tto_logo":"/image_cloud/yissum_tto_logo_0151a5c5-6017-11e8-b269-41fdcbb0dda6","university_logo":"/image_cloud/yissum_institution_logo_0151a5c5-6017-11e8-b269-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["Promitil"],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":0,"lastfunding":"$56K","totalrounds":1,"fundingstage":"Pre-Funding","totalfunding":"$56K","publicinvestors":0,"lastpublicfunding":56000,"totalpublicrounds":1,"totalpublicfunding":56000},"team":[{"name":"Al Gabizon","email":"alberto.gabizon@lipomedix.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0IcIDA","bounced":false,"claimed":1,"founder":1,"urlname":"alberto-gabizon","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICA3vavvgsM","position":"Founder &  President","last_name":"Gabizon","claimtoken":"86ebc33c253d25066e6853ac87c585b7ee33081e249467f690fdbe262ac72301","first_name":"Al","picturekey":null,"claimeddate":"2019-02-08","linkedinurl":"https://www.linkedin.com/in/al-gabizon-092010122","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2019-02-08 10:52:30.000000","initials":"AG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Rami  Kremien","email":"rami.kremien@lipomedix.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4IKekq8IDA","bounced":true,"claimed":0,"founder":1,"urlname":"rami-kremien","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgoq_ppAkM","position":"Co-founder","last_name":"Kremien","claimtoken":"e913c7cdcfb76bffef19f89a840a7bbb6c5bf98299cf3a3d454fa3da5175e7fd","first_name":"Rami ","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-10-11 09:20:57.000000","initials":"RK","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Patricia Ohana","email":"patriciaohana18@gmail.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgJ63_pcIDA","bounced":false,"claimed":1,"founder":0,"urlname":"patricia-ohana","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAvsTf6woM","position":"VP Clinical Affairs","last_name":"Ohana","claimtoken":"aebce170af9928b8d17d6606a9feafe323590ea5f2b6593be60811887e1f5ee3","first_name":"Patricia","picturekey":null,"claimeddate":"2014-12-03","linkedinurl":"https://www.linkedin.com/pub/patricia-ohana/10/1a6/812","unsubscribed":false,"is_activeuser":1,"additionalemail":"patricia.ohana@lipomedix.com","claimedemaildate":null,"initials":"PO","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Aviva Fridman","email":"","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4OKM_sIKDA","bounced":false,"claimed":0,"founder":0,"urlname":"aviva-fridman","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDggp6SzwsM","position":"Freelance Project Manager","last_name":"Fridman","claimtoken":"7d25227c8ab66483987e9ccd1918d0821adcf3f52da55e1c5499167bd94a7297","first_name":"Aviva","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/aviva-fridman-7aba18b/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-01-15 14:59:53.000000","initials":"AF","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverifydate":"2020-01-15T00:00:00.000Z","crunchbaseid":"lipomedix","lastupdator":"Natasha Voloshin","lastupdator_email":"natashavolo@gmail.com","creator":"Sharon Shapira","creator_email":"shapira.sharon2@gmail.com","createdate":"2014-12-03T00:00:00.000Z","biverification":"Sharon Shapira","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD-wI6QCQw","date":"Jul 2019","amount":"$56K","source":"http://lipomedix.com/Announcements","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"European Commission","type":"Company","amount":56000,"hidden":true,"country":"Belgium","fullurl":"/company_page/european-commission","logokey":"$E7bRUi5i2O7c40Iisf5CTwRqUu10LyEfJVqIEKIadDQCfpmJCGaaAG","tagline":"","urlname":"/company_page/european-commission","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC4jqaLCAw","fundingtype":"Company","leadpartner":null,"investmentid":"0535586a-9565-4e6e-bba7-34d6d5342ad2","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$E7bRUi5i2O7c40Iisf5CTwRqUu10LyEfJVqIEKIadDQCfpmJCGaaAG","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":56000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"6/2011","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"LipoMedix","logourl":"https://storage.googleapis.com/clean-finder-353810/$l6sd6NdYllN9AJYbWihtQc1L0HIw2YB2MbyYsAcQJAUMa8IIc4O0E7","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$l6sd6NdYllN9AJYbWihtQc1L0HIw2YB2MbyYsAcQJAUMa8IIc4O0E7","seoabout":"LipoMedix Pharmaceuticals is a privately held development-stage company focused on an innovative, safe, and effective cancer therapy based on liposome deli...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drug Delivery","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drug Delivery"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drug Delivery"],"coreTechnology":["Biologicals"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD-wI6QCQw","date":"Jul 2019","amount":"$56K","source":"http://lipomedix.com/Announcements","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"European Commission","type":"Company","amount":56000,"hidden":true,"country":"Belgium","fullurl":"/company_page/european-commission","logokey":"$E7bRUi5i2O7c40Iisf5CTwRqUu10LyEfJVqIEKIadDQCfpmJCGaaAG","tagline":"","urlname":"/company_page/european-commission","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC4jqaLCAw","fundingtype":"Company","leadpartner":null,"investmentid":"0535586a-9565-4e6e-bba7-34d6d5342ad2","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$E7bRUi5i2O7c40Iisf5CTwRqUu10LyEfJVqIEKIadDQCfpmJCGaaAG","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":56000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}